Cargando…
晚期非小细胞肺癌三线治疗疗效及生存分析
BACKGROUND AND OBJECTIVE: The appearance of highly effective and low toxic drugs enables an increasing number of advanced non-small cell lung cancer (NSCLC) patients to receive third-line therapy. No other standard choice for third-line therapy aside from erlotinib is possible. This study respective...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000300/ https://www.ncbi.nlm.nih.gov/pubmed/22681924 http://dx.doi.org/10.3779/j.issn.1009-3419.2012.06.08 |